Invention Grant
US09439944B2 Agent that inhibits angiogenesis and metastasis targeting mTOR signaling pathway
有权
抑制血管发生和转移靶向mTOR信号通路的药物
- Patent Title: Agent that inhibits angiogenesis and metastasis targeting mTOR signaling pathway
- Patent Title (中): 抑制血管发生和转移靶向mTOR信号通路的药物
-
Application No.: US12107492Application Date: 2008-04-22
-
Publication No.: US09439944B2Publication Date: 2016-09-13
- Inventor: Kyoungsook Park , Je-Ho Lee , Kyusam Choi
- Applicant: Kyoungsook Park , Je-Ho Lee , Kyusam Choi
- Applicant Address: KR Suwon-Shi
- Assignee: SUNGYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION
- Current Assignee: SUNGYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION
- Current Assignee Address: KR Suwon-Shi
- Agency: Lex IP Meister, PLLC
- Main IPC: A61K38/17
- IPC: A61K38/17 ; A61P35/00 ; A61K38/16
Abstract:
The present invention relates to a novel function of Msx1 protein for inhibiting tumor angiogenesis and metastasis by targeting mTOR (mammalian target of rapamycin) signaling pathway, and for treating a cancer in a subject. Particularly, Msx1 suppresses mTOR through a direct interaction with mTOR, resulting in the inhibition of angiogenesis. The Msx1 significantly suppresses tumor angiogenesis that is necessary for the growth, invasion, and metastasis of solid tumors. Ad-Msx1 can be used to effectively inhibit tumor metastasis by suppressing angiogenesis, tumor cell invasion, and migration.
Public/Granted literature
- US20090264357A1 NOVEL AGENT THAT INHIBITS ANGIOGENESIS AND METASTASIS TARGETING mTOR SIGNALING PATHWAY Public/Granted day:2009-10-22
Information query
IPC分类:
